While clinical research furthers its quest in proving psychedelics’ potential in treating a variety of psychiatric disorders, the debate now is the importance of psychological support in trials investigating psychedelic-assisted therapy.
“MDMA-assisted therapy for PTSD is on track to be considered for approval by the FDA in 2024,” says MAPS founder and president Rick Doblin.
In yet another eventful week in the psychedelics sphere, more clear signs depict psychedelics’ popularity and acceptance.
The Food and Drug Administration published a new draft guidance with the purpose to advise researchers on study design when investigating the potential of psychedelics.
This trial, using Filament Health’s botanical drug candidates, is the first to assess the direct administration of psilocin.
This week in psychedelic business news: MindMed’s MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
“This study of ketamine’s psychedelic effects while wearing headgear equipped with sensors to record brain activity could open up new frontiers of understanding,” says Cybin’s chief clinical officer.
“This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine,” says PharmaTher CEO Fabio Chianelli.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.